Meeting
2022 ASCO Annual Meeting
Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC).
Authors
Fabrice Andre
Gustave Roussy, Université Paris-Sud, Villejuif, France
Fabrice Andre , Erika P. Hamilton , Sherene Loi , Seock-Ah Im , Joohyuk Sohn , Ling-Ming Tseng , Carey K. Anders , Peter Schmid , Sarice Boston , Annie Darilay , Pia Maarit Herbolsheimer , Adam Konpa , Gargi Patel , Tinghui Yu , Magdalena Wrona , Komal L. Jhaveri
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Chemotherapy and Antibody-Drug Conjugates
Clinical Trial Registration Number
NCT04538742; NCT04556773
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 3025)
DOI
10.1200/JCO.2022.40.16_suppl.3025
Abstract #
3025
Poster Bd #
17
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study.
First Author: Hossein Borghaei
Poster
2015 ASCO Annual Meeting
Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC).
First Author: Payal Deepak Shah
First Author: Nicholas Patrick McAndrew
Poster
2023 ASCO Annual Meeting
A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors.
First Author: Sara A. Hurvitz